RYTM Rhythm Pharmaceuticals Inc.

17.97
-0.41  -2%
Previous Close 18.38
Open 18.49
Price To Book 5.3
Market Cap 789,357,516
Shares 43,926,406
Volume 243,070
Short Ratio
Av. Daily Volume 283,501
Stock charts supplied by TradingView

NewsSee all news

  1. Rhythm Pharmaceuticals Announces Leadership Transition

    Keith Gottesdiener, M.D. to Step Down as Chief Executive Officer Following NDA Submission for Setmelanotide in POMC and LEPR Deficiency Obesities Expected in the First Quarter of 2020 Board Forms Search Committee to

  2. Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

    -- Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 -- -- Supplemental cohort continues enrollment to meet patient demand -- BOSTON, Dec. 05, 2019 (GLOBE NEWSWIRE) --  Rhythm

  3. Rhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference

    BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of

  4. Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019

    -- Data show treatment effect of setmelanotide on additional secondary endpoints, including body mass index --  -- Additional safety analyses show no significant increases in heart rate or blood pressure -- -- Two oral

  5. Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results

    -- Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities -- -- Added Four New MC4R Pathway Obesity Indications to Phase 2 Basket Study and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 update September 25, 2019. Mean weight reduction in 6/9 patients of 22.2%.
Setmelanotide (basket)
POMC Heterozygous Deficiency Obesity, Alstrom Syndrome, POMC Epigenetic Disorders
Phase 3 completion of enrolment announced December 5, 2019 with top-line data due 4Q 2020 or 1Q 2021.
Setmelanotide
Alstrom Syndrome and Bardet-Biedl Syndrome
NDA filing due 1Q 2020.
Setmelanotide
Leptin Receptor Deficiency Obesity
NDA filing due 1Q 2020.
Setmelanotide
POMC deficiency obesity

Latest News

  1. Rhythm Pharmaceuticals Announces Leadership Transition

    Keith Gottesdiener, M.D. to Step Down as Chief Executive Officer Following NDA Submission for Setmelanotide in POMC and LEPR Deficiency Obesities Expected in the First Quarter of 2020 Board Forms Search Committee to

  2. Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

    -- Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 -- -- Supplemental cohort continues enrollment to meet patient demand -- BOSTON, Dec. 05, 2019 (GLOBE NEWSWIRE) --  Rhythm

  3. Rhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference

    BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of

  4. Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019

    -- Data show treatment effect of setmelanotide on additional secondary endpoints, including body mass index --  -- Additional safety analyses show no significant increases in heart rate or blood pressure -- -- Two oral

  5. Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results

    -- Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities -- -- Added Four New MC4R Pathway Obesity Indications to Phase 2 Basket Study and

  6. Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ObesityWeek® 2019

    BOSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of

  7. Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

    BOSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic

  8. Rhythm Pharmaceuticals Provides Update on Research and Development Programs

    -- Four new MC4R pathway obesity indications added to Phase 2 Basket Study and enrolling patients -- -- Genetic sequencing of 13,567 individuals with severe obesity yields 11.7 percent (1,584 individuals) who have a

  9. Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders

    -- Plan to expand ongoing Phase 2 Basket Study with four additional rare indications ---- Sequenced nearly 14,000 people with early-onset, severe obesity; Yield suggests potential significant opportunity for

  10. Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in September

    BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of